Work

Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions

Year: 2017

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2017-ct060

Authors: Alexander Drilon, Kamalesh Kumar Sankhala, Stephen V. Liu, Byoung Chul Cho, Collin Blakely, Cheng E. Chee, Marwan Fakih, Jonathan Polikoff, Zachary Hornby, Lisa Schechet, David Luo, Edna Chow Maneval, Pratik S. Multani, Robert C. Doebele

Institutions: Memorial Sloan Kettering Cancer Center, Sarcoma Oncology Center, Georgetown Lombardi Comprehensive Cancer Center, Yonsei Cancer Hospital, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, National University Cancer Institute, Singapore, City Of Hope National Medical Center, Kaiser Permanente, Kaiser Permanente San Diego Medical Center, Ignyta (United States), University of Colorado Anschutz

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2741250160

Cites:

Cited by: 18

Related to: 10